NewslettersSep 30, 2026
Porton Newsletter - September, 2026 Recap
Porton Recognized by LyncBio Therapeutics for ADC Payload-Linker CMC Capabilities Porton Chongqing Liangjiang Drug Product Manufacturing Site Earns Recertification of ISO 14001 & ISO 45001 PMO Therapeutics: Technical Review and Manufacturing Platform Capabilities
News Sep 29, 2026
Porton Recognized by LyncBio Therapeutics for ADC Payload-Linker CMC Capabilities
Porton, as the project's CDMO partner, completed process development and manufactured non-GMP toxicology batches and GMP clinical trial materials for LYNC-101's payload-linker.
News Sep 15, 2026
Porton Chongqing Liangjiang Drug Product Manufacturing Site Earns Recertification of ISO 14001 & ISO 45001
This successful recertification highlights the standardized operation of the site's management systems, the rigor of its on-site management, and the robustness of its risk control mechanisms, further validating the continued effectiveness of the dual systems.
News Sep 01, 2026
Porton to Showcase End-to-End CDMO Expertise at CPHI Milan 2026
CPHI creates connections and inspires partnerships across the global pharma community, championing innovation at the heart of pharma through in-person and online events that grant access to endless opportunities.
NewslettersAug 31, 2026
Porton Newsletter - August 2026 Recap
Porton Reports H1 2026 Results Porton Appoints Dr. Yongli Zhong as Chief Scientific Officer Porton Appoints Yunxing Yin as Corporate Vice President to Strengthen Small-Molecule R&D Leadership
NewslettersJul 31, 2026
Porton Newsletter - July 2026 Recap
Antibody-Oligonucleotide Conjugates: From Conjugation Strategy to Purification and Analytical Control Porton Named as a Constituent of the FTSE4Good Index Series
News Jul 08, 2026
Porton Advanced's UC-MSCs Cell Bank for Exosome Manufacturing Receives U.S. FDA Drug Master File (DMF) Acceptance
Porton Advanced's UC-MSCs Cell Bank for Exosome Manufacturing Receives U.S. FDA Drug Master File (DMF) Acceptance
News Jul 03, 2026
Porton Delivers Dual-Payload ADC IND, Advancing Next-generation Conjugate Drug Development
Porton One-stop Biologics and Conjugates CDMO Platform successfully completed the full-cycle delivery of process development and GMP IND clinical sample manufacturing for a dual-payload ADC.
News Jul 02, 2026
Porton Highlights Integrated CDMO Capabilities at BIO International Convention 2026 and Celebrates Porton J-STAR's 30th Anniversary
Porton Highlights Integrated CDMO Capabilities at BIO International Convention 2026 and Celebrates Porton J-STAR’s 30th Anniversary
